Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Mycoses | 8 | 2018 | 386 | 2.290 |
Why?
|
Antifungal Agents | 10 | 2022 | 761 | 1.720 |
Why?
|
Aspergillosis | 7 | 2019 | 242 | 1.680 |
Why?
|
Mannans | 4 | 2018 | 58 | 1.560 |
Why?
|
beta-Glucans | 7 | 2020 | 129 | 1.370 |
Why?
|
Volatile Organic Compounds | 2 | 2021 | 86 | 0.830 |
Why?
|
Communicable Diseases | 3 | 2021 | 873 | 0.770 |
Why?
|
Ascomycota | 2 | 2012 | 81 | 0.720 |
Why?
|
Breath Tests | 2 | 2021 | 300 | 0.710 |
Why?
|
Pulmonary Aspergillosis | 1 | 2018 | 48 | 0.600 |
Why?
|
False Positive Reactions | 2 | 2018 | 963 | 0.590 |
Why?
|
Immunocompromised Host | 5 | 2015 | 863 | 0.560 |
Why?
|
Lymphoma, Non-Hodgkin | 3 | 2022 | 1376 | 0.540 |
Why?
|
Bronchoalveolar Lavage Fluid | 1 | 2018 | 761 | 0.530 |
Why?
|
Disk Diffusion Antimicrobial Tests | 1 | 2015 | 9 | 0.520 |
Why?
|
Candidemia | 1 | 2015 | 40 | 0.500 |
Why?
|
Fluconazole | 1 | 2015 | 156 | 0.490 |
Why?
|
Cephalosporins | 1 | 2016 | 200 | 0.480 |
Why?
|
Lung Transplantation | 3 | 2017 | 1309 | 0.480 |
Why?
|
Neuralgia, Postherpetic | 1 | 2013 | 41 | 0.440 |
Why?
|
Antigens, Fungal | 2 | 2012 | 69 | 0.440 |
Why?
|
Aspergillus fumigatus | 1 | 2014 | 158 | 0.430 |
Why?
|
Clinical Laboratory Techniques | 1 | 2018 | 749 | 0.430 |
Why?
|
Pneumonia, Pneumocystis | 2 | 2012 | 242 | 0.410 |
Why?
|
Opportunistic Infections | 1 | 2015 | 375 | 0.410 |
Why?
|
Parainfluenza Virus 3, Human | 1 | 2012 | 25 | 0.400 |
Why?
|
Heart Transplantation | 3 | 2017 | 3301 | 0.400 |
Why?
|
Candidiasis, Invasive | 1 | 2012 | 26 | 0.400 |
Why?
|
Paramyxoviridae Infections | 1 | 2012 | 57 | 0.390 |
Why?
|
Anti-Infective Agents, Local | 1 | 2014 | 247 | 0.380 |
Why?
|
Mycophenolic Acid | 1 | 2013 | 348 | 0.380 |
Why?
|
Herpes Zoster | 1 | 2013 | 252 | 0.370 |
Why?
|
Central Nervous System Fungal Infections | 1 | 2010 | 24 | 0.360 |
Why?
|
Neutropenia | 1 | 2016 | 893 | 0.360 |
Why?
|
Galactose | 4 | 2018 | 300 | 0.360 |
Why?
|
Hematologic Neoplasms | 4 | 2020 | 1907 | 0.350 |
Why?
|
Cytomegalovirus Infections | 5 | 2020 | 839 | 0.350 |
Why?
|
Cellulitis | 1 | 2012 | 206 | 0.340 |
Why?
|
Myositis | 1 | 2012 | 269 | 0.320 |
Why?
|
Catheterization, Central Venous | 1 | 2014 | 536 | 0.310 |
Why?
|
Triazoles | 4 | 2019 | 904 | 0.310 |
Why?
|
Cord Blood Stem Cell Transplantation | 3 | 2018 | 305 | 0.300 |
Why?
|
Ethanol | 1 | 2014 | 1331 | 0.290 |
Why?
|
Transplantation, Homologous | 6 | 2018 | 4835 | 0.290 |
Why?
|
Hematopoietic Stem Cell Transplantation | 6 | 2022 | 5716 | 0.290 |
Why?
|
Cytomegalovirus | 4 | 2020 | 753 | 0.270 |
Why?
|
Immunosuppressive Agents | 4 | 2013 | 4207 | 0.260 |
Why?
|
Recombinant Fusion Proteins | 2 | 2012 | 3744 | 0.250 |
Why?
|
Anti-Bacterial Agents | 3 | 2024 | 7478 | 0.240 |
Why?
|
Proteoglycans | 5 | 2012 | 809 | 0.240 |
Why?
|
Candidiasis | 2 | 2021 | 367 | 0.230 |
Why?
|
Organ Transplantation | 4 | 2024 | 1178 | 0.220 |
Why?
|
Extracorporeal Membrane Oxygenation | 3 | 2020 | 1483 | 0.220 |
Why?
|
Frontal Lobe | 1 | 2010 | 1426 | 0.220 |
Why?
|
Graft Rejection | 2 | 2013 | 4492 | 0.210 |
Why?
|
Physicians | 1 | 2021 | 4607 | 0.210 |
Why?
|
Aged | 33 | 2024 | 171786 | 0.210 |
Why?
|
Immunologic Factors | 2 | 2018 | 1597 | 0.200 |
Why?
|
Gram-Negative Bacterial Infections | 1 | 2024 | 238 | 0.200 |
Why?
|
Immunoassay | 2 | 2020 | 746 | 0.200 |
Why?
|
Antibodies, Monoclonal | 2 | 2010 | 9264 | 0.200 |
Why?
|
Middle Aged | 36 | 2024 | 223737 | 0.190 |
Why?
|
Histoplasma | 2 | 2011 | 40 | 0.190 |
Why?
|
Histoplasmosis | 2 | 2011 | 64 | 0.190 |
Why?
|
Cardiomyopathies | 1 | 2013 | 2057 | 0.180 |
Why?
|
Young Adult | 13 | 2020 | 60131 | 0.180 |
Why?
|
Adult | 30 | 2024 | 223851 | 0.170 |
Why?
|
Glucans | 1 | 2020 | 71 | 0.170 |
Why?
|
Respiratory Insufficiency | 2 | 2019 | 1241 | 0.170 |
Why?
|
Transplants | 1 | 2022 | 209 | 0.170 |
Why?
|
Sepsis | 1 | 2014 | 2610 | 0.170 |
Why?
|
Humans | 57 | 2024 | 768970 | 0.170 |
Why?
|
Male | 39 | 2024 | 365203 | 0.170 |
Why?
|
Leukemia | 1 | 2008 | 1520 | 0.170 |
Why?
|
Pneumocystis carinii | 2 | 2012 | 72 | 0.160 |
Why?
|
Aged, 80 and over | 12 | 2020 | 59739 | 0.160 |
Why?
|
Polydeoxyribonucleotides | 1 | 2020 | 136 | 0.160 |
Why?
|
Adrenal Glands | 2 | 2011 | 557 | 0.160 |
Why?
|
Fever | 3 | 2018 | 1619 | 0.160 |
Why?
|
Lymphoma | 1 | 2008 | 1900 | 0.150 |
Why?
|
Orchitis | 1 | 2018 | 36 | 0.150 |
Why?
|
Respiratory Tract Infections | 2 | 2020 | 1014 | 0.150 |
Why?
|
Female | 34 | 2024 | 397515 | 0.150 |
Why?
|
Encephalitis, Tick-Borne | 1 | 2018 | 45 | 0.150 |
Why?
|
Uveitis | 2 | 2011 | 398 | 0.150 |
Why?
|
Encephalitis Viruses, Tick-Borne | 1 | 2018 | 48 | 0.150 |
Why?
|
Molecular Diagnostic Techniques | 3 | 2020 | 620 | 0.140 |
Why?
|
Encephalitozoon cuniculi | 1 | 2017 | 5 | 0.140 |
Why?
|
Bacteremia | 1 | 2024 | 985 | 0.140 |
Why?
|
Microsporidiosis | 1 | 2017 | 23 | 0.140 |
Why?
|
Cohort Studies | 11 | 2019 | 41808 | 0.140 |
Why?
|
Photopheresis | 1 | 2017 | 35 | 0.140 |
Why?
|
Viruses | 1 | 2020 | 373 | 0.140 |
Why?
|
Anticoagulants | 4 | 2005 | 4850 | 0.140 |
Why?
|
Heart Defects, Congenital | 1 | 2013 | 4712 | 0.140 |
Why?
|
Propensity Score | 1 | 2024 | 1968 | 0.130 |
Why?
|
Primary Graft Dysfunction | 1 | 2017 | 112 | 0.130 |
Why?
|
Treatment Outcome | 13 | 2024 | 65480 | 0.130 |
Why?
|
Incidence | 6 | 2022 | 21547 | 0.130 |
Why?
|
Retrospective Studies | 14 | 2024 | 81903 | 0.130 |
Why?
|
Hemorrhage | 2 | 2004 | 3466 | 0.120 |
Why?
|
Cyclohexenes | 1 | 2014 | 15 | 0.120 |
Why?
|
Lung Diseases, Fungal | 1 | 2015 | 124 | 0.120 |
Why?
|
Monoterpenes | 1 | 2014 | 22 | 0.120 |
Why?
|
Antineoplastic Agents | 3 | 2019 | 13698 | 0.120 |
Why?
|
Risk Factors | 10 | 2022 | 74976 | 0.120 |
Why?
|
Terpenes | 1 | 2014 | 102 | 0.120 |
Why?
|
Gas Chromatography-Mass Spectrometry | 1 | 2014 | 354 | 0.110 |
Why?
|
Decision Trees | 1 | 2015 | 509 | 0.110 |
Why?
|
Sesquiterpenes | 1 | 2014 | 177 | 0.110 |
Why?
|
Herpes Zoster Ophthalmicus | 1 | 2013 | 37 | 0.110 |
Why?
|
Species Specificity | 1 | 2018 | 2417 | 0.110 |
Why?
|
Leukemia, Prolymphocytic, T-Cell | 1 | 2013 | 23 | 0.110 |
Why?
|
Encephalomyelitis | 1 | 2013 | 37 | 0.110 |
Why?
|
Ganciclovir | 1 | 2013 | 256 | 0.110 |
Why?
|
Encephalitis | 1 | 2017 | 441 | 0.110 |
Why?
|
Immunomodulation | 1 | 2017 | 549 | 0.110 |
Why?
|
Adenoviridae Infections | 1 | 2013 | 96 | 0.100 |
Why?
|
DNA, Ribosomal Spacer | 1 | 2012 | 27 | 0.100 |
Why?
|
Reagent Strips | 1 | 2012 | 40 | 0.100 |
Why?
|
Echinocandins | 1 | 2012 | 54 | 0.100 |
Why?
|
Lipopeptides | 1 | 2012 | 71 | 0.100 |
Why?
|
Tissue Transplantation | 1 | 2012 | 128 | 0.100 |
Why?
|
Serum | 2 | 2011 | 207 | 0.100 |
Why?
|
Cystectomy | 1 | 2017 | 645 | 0.100 |
Why?
|
Amphotericin B | 1 | 2012 | 143 | 0.100 |
Why?
|
Limbic Encephalitis | 1 | 2012 | 36 | 0.100 |
Why?
|
Epidemiologic Studies | 1 | 2015 | 677 | 0.100 |
Why?
|
Marital Status | 1 | 2013 | 426 | 0.100 |
Why?
|
Cytosine | 1 | 2013 | 213 | 0.100 |
Why?
|
Immunotherapy | 1 | 2008 | 4756 | 0.100 |
Why?
|
Aspergillus | 1 | 2012 | 95 | 0.100 |
Why?
|
Roseolovirus Infections | 1 | 2012 | 50 | 0.100 |
Why?
|
Antibiotic Prophylaxis | 1 | 2017 | 641 | 0.100 |
Why?
|
Herpesvirus 6, Human | 1 | 2012 | 98 | 0.100 |
Why?
|
Drug Administration Schedule | 3 | 2015 | 4862 | 0.090 |
Why?
|
Candida | 1 | 2012 | 173 | 0.090 |
Why?
|
Equipment Contamination | 1 | 2012 | 183 | 0.090 |
Why?
|
DNA, Ribosomal | 1 | 2012 | 300 | 0.090 |
Why?
|
DNA, Fungal | 1 | 2012 | 275 | 0.090 |
Why?
|
Early Diagnosis | 1 | 2015 | 1194 | 0.090 |
Why?
|
Time Factors | 7 | 2019 | 40261 | 0.080 |
Why?
|
Costs and Cost Analysis | 1 | 2015 | 1669 | 0.080 |
Why?
|
Diagnostic Tests, Routine | 1 | 2015 | 790 | 0.080 |
Why?
|
Anti-Infective Agents | 2 | 2014 | 984 | 0.080 |
Why?
|
Graft vs Host Disease | 3 | 2012 | 3048 | 0.080 |
Why?
|
Histocytochemistry | 1 | 2010 | 699 | 0.080 |
Why?
|
Dacarbazine | 1 | 2012 | 559 | 0.080 |
Why?
|
Kidney Transplantation | 2 | 2017 | 4265 | 0.080 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 2 | 2010 | 696 | 0.080 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2012 | 618 | 0.070 |
Why?
|
Seminal Vesicles | 2 | 2005 | 103 | 0.070 |
Why?
|
Drug Costs | 1 | 2015 | 1198 | 0.070 |
Why?
|
Fatal Outcome | 3 | 2018 | 1836 | 0.070 |
Why?
|
Respiration, Artificial | 1 | 2019 | 2725 | 0.070 |
Why?
|
Aminoglycosides | 1 | 2008 | 161 | 0.070 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2020 | 4413 | 0.070 |
Why?
|
Tissue Donors | 1 | 2017 | 2382 | 0.070 |
Why?
|
Leg | 1 | 2012 | 1089 | 0.070 |
Why?
|
Lung Diseases | 1 | 2017 | 1944 | 0.070 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2010 | 453 | 0.070 |
Why?
|
Republic of Korea | 2 | 2019 | 592 | 0.070 |
Why?
|
Face | 1 | 2012 | 1031 | 0.070 |
Why?
|
Guideline Adherence | 1 | 2017 | 2241 | 0.070 |
Why?
|
Multivariate Analysis | 2 | 2019 | 12095 | 0.070 |
Why?
|
Antibodies, Neoplasm | 1 | 2008 | 283 | 0.070 |
Why?
|
Immunity, Humoral | 1 | 2010 | 610 | 0.070 |
Why?
|
Proportional Hazards Models | 3 | 2020 | 12562 | 0.060 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2020 | 4651 | 0.060 |
Why?
|
Warfarin | 2 | 2004 | 1493 | 0.060 |
Why?
|
Combined Modality Therapy | 2 | 2017 | 8559 | 0.060 |
Why?
|
Survival Rate | 3 | 2019 | 12873 | 0.060 |
Why?
|
Treatment Failure | 1 | 2012 | 2664 | 0.060 |
Why?
|
Academic Medical Centers | 1 | 2016 | 2784 | 0.060 |
Why?
|
Microscopy | 1 | 2010 | 910 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2015 | 10400 | 0.060 |
Why?
|
Sirolimus | 1 | 2012 | 1540 | 0.060 |
Why?
|
Prostate-Specific Antigen | 2 | 2005 | 2487 | 0.060 |
Why?
|
Cluster Analysis | 1 | 2012 | 2732 | 0.060 |
Why?
|
Radiotherapy, Conformal | 2 | 2005 | 549 | 0.060 |
Why?
|
Prognosis | 4 | 2020 | 30046 | 0.060 |
Why?
|
Liver Transplantation | 1 | 2017 | 2403 | 0.060 |
Why?
|
Boston | 2 | 2016 | 9377 | 0.060 |
Why?
|
Feasibility Studies | 1 | 2015 | 5323 | 0.060 |
Why?
|
Diagnostic Errors | 1 | 2011 | 1281 | 0.060 |
Why?
|
Adolescent | 7 | 2020 | 89244 | 0.060 |
Why?
|
Kinetics | 1 | 2012 | 6332 | 0.060 |
Why?
|
Phylogeny | 1 | 2012 | 2843 | 0.060 |
Why?
|
Antiviral Agents | 2 | 2013 | 3070 | 0.060 |
Why?
|
Thromboembolism | 3 | 2005 | 1004 | 0.060 |
Why?
|
Medication Systems, Hospital | 1 | 2004 | 154 | 0.060 |
Why?
|
Sensitivity and Specificity | 2 | 2009 | 14752 | 0.050 |
Why?
|
Surgical Wound Infection | 1 | 2012 | 1547 | 0.050 |
Why?
|
Bandages | 1 | 2005 | 273 | 0.050 |
Why?
|
Recurrence | 1 | 2015 | 8513 | 0.050 |
Why?
|
Influenza Vaccines | 1 | 2010 | 781 | 0.050 |
Why?
|
Drug Therapy, Computer-Assisted | 1 | 2004 | 197 | 0.050 |
Why?
|
Adrenal Cortex Hormones | 1 | 2012 | 1892 | 0.050 |
Why?
|
Waldenstrom Macroglobulinemia | 1 | 2011 | 1077 | 0.050 |
Why?
|
Cost-Benefit Analysis | 1 | 2015 | 5544 | 0.050 |
Why?
|
Postoperative Complications | 2 | 2017 | 15889 | 0.050 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2004 | 344 | 0.050 |
Why?
|
Health Care Costs | 1 | 2015 | 3270 | 0.050 |
Why?
|
Anti-Inflammatory Agents | 1 | 2012 | 1811 | 0.050 |
Why?
|
Predictive Value of Tests | 1 | 2018 | 15471 | 0.050 |
Why?
|
Reminder Systems | 1 | 2005 | 388 | 0.050 |
Why?
|
Massachusetts | 1 | 2014 | 8894 | 0.050 |
Why?
|
Cause of Death | 1 | 2012 | 3721 | 0.050 |
Why?
|
Sequence Analysis, DNA | 1 | 2012 | 4785 | 0.040 |
Why?
|
GATA2 Transcription Factor | 1 | 2021 | 158 | 0.040 |
Why?
|
Risk | 1 | 2012 | 9621 | 0.040 |
Why?
|
Heparin | 2 | 2004 | 1636 | 0.040 |
Why?
|
Sex Factors | 1 | 2013 | 10633 | 0.040 |
Why?
|
Stem Cell Transplantation | 1 | 2008 | 1602 | 0.040 |
Why?
|
Antigens, CD19 | 1 | 2022 | 446 | 0.040 |
Why?
|
Influenza, Human | 1 | 2010 | 1542 | 0.040 |
Why?
|
Radiography | 1 | 2010 | 6991 | 0.040 |
Why?
|
Molecular Sequence Data | 1 | 2012 | 17629 | 0.040 |
Why?
|
Antibodies, Viral | 1 | 2010 | 3215 | 0.040 |
Why?
|
Myasthenia Gravis | 2 | 2011 | 217 | 0.040 |
Why?
|
North America | 1 | 2022 | 1290 | 0.040 |
Why?
|
Neoplasms | 2 | 2021 | 22389 | 0.040 |
Why?
|
APACHE | 1 | 2019 | 268 | 0.040 |
Why?
|
Cell Count | 1 | 2022 | 1833 | 0.040 |
Why?
|
Medication Errors | 1 | 2004 | 785 | 0.040 |
Why?
|
Follow-Up Studies | 4 | 2014 | 39394 | 0.040 |
Why?
|
Pyrimidines | 1 | 2010 | 3048 | 0.040 |
Why?
|
Diagnostic Techniques and Procedures | 1 | 2020 | 219 | 0.040 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 11886 | 0.040 |
Why?
|
Statistics, Nonparametric | 2 | 2019 | 2862 | 0.040 |
Why?
|
Blood Glucose | 1 | 2012 | 6435 | 0.040 |
Why?
|
Length of Stay | 2 | 2024 | 6526 | 0.040 |
Why?
|
Adenocarcinoma | 2 | 2005 | 6401 | 0.030 |
Why?
|
Age Factors | 1 | 2013 | 18435 | 0.030 |
Why?
|
Glioblastoma | 1 | 2012 | 3525 | 0.030 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2008 | 1642 | 0.030 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2008 | 4356 | 0.030 |
Why?
|
Administration, Oral | 1 | 2024 | 4040 | 0.030 |
Why?
|
Risk Assessment | 3 | 2014 | 24333 | 0.030 |
Why?
|
Prospective Studies | 2 | 2014 | 54962 | 0.030 |
Why?
|
Area Under Curve | 1 | 2020 | 1645 | 0.030 |
Why?
|
Decision Support Systems, Clinical | 1 | 2005 | 1178 | 0.030 |
Why?
|
Hospital Mortality | 2 | 2020 | 5369 | 0.030 |
Why?
|
Venous Thrombosis | 1 | 2005 | 1321 | 0.030 |
Why?
|
Acute Disease | 2 | 2019 | 7245 | 0.030 |
Why?
|
Fatigue | 2 | 2011 | 1557 | 0.030 |
Why?
|
Nitriles | 1 | 2019 | 990 | 0.030 |
Why?
|
Software | 2 | 2005 | 4479 | 0.030 |
Why?
|
Multiple Myeloma | 1 | 2011 | 5196 | 0.030 |
Why?
|
Bacteria, Aerobic | 1 | 2012 | 24 | 0.030 |
Why?
|
Chi-Square Distribution | 1 | 2019 | 3438 | 0.030 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 686 | 0.030 |
Why?
|
Herpesvirus 4, Human | 1 | 1998 | 1082 | 0.030 |
Why?
|
Consensus | 1 | 2022 | 3214 | 0.030 |
Why?
|
Bacteria, Anaerobic | 1 | 2012 | 71 | 0.020 |
Why?
|
Immunotherapy, Adoptive | 1 | 2022 | 1520 | 0.020 |
Why?
|
ROC Curve | 1 | 2020 | 3629 | 0.020 |
Why?
|
Prostatic Neoplasms | 2 | 2005 | 11230 | 0.020 |
Why?
|
Drug Dosage Calculations | 1 | 2012 | 117 | 0.020 |
Why?
|
Phlebotomy | 1 | 2012 | 138 | 0.020 |
Why?
|
Fetal Blood | 1 | 2018 | 1361 | 0.020 |
Why?
|
Pulmonary Embolism | 1 | 2005 | 2600 | 0.020 |
Why?
|
Severity of Illness Index | 3 | 2019 | 15951 | 0.020 |
Why?
|
Hodgkin Disease | 1 | 1998 | 1384 | 0.020 |
Why?
|
Virus Activation | 1 | 2012 | 324 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 2 | 2010 | 36854 | 0.020 |
Why?
|
Weight Loss | 2 | 2011 | 2721 | 0.020 |
Why?
|
United States | 3 | 2017 | 73186 | 0.020 |
Why?
|
Linear Models | 1 | 2020 | 5891 | 0.020 |
Why?
|
Catheter-Related Infections | 1 | 2012 | 275 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2020 | 5906 | 0.020 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 1560 | 0.020 |
Why?
|
SEER Program | 1 | 2013 | 1473 | 0.020 |
Why?
|
Drug Synergism | 1 | 2012 | 1762 | 0.020 |
Why?
|
Radiotherapy Dosage | 2 | 2005 | 2921 | 0.020 |
Why?
|
Pyridines | 1 | 2019 | 2895 | 0.020 |
Why?
|
Cytokines | 1 | 2020 | 7453 | 0.010 |
Why?
|
Disease-Free Survival | 2 | 2005 | 6856 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2012 | 6236 | 0.010 |
Why?
|
Social Support | 1 | 2013 | 2193 | 0.010 |
Why?
|
Hospital Information Systems | 1 | 2005 | 394 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2012 | 6320 | 0.010 |
Why?
|
Chronic Disease | 1 | 2017 | 9384 | 0.010 |
Why?
|
Graft Survival | 1 | 2012 | 3888 | 0.010 |
Why?
|
Odds Ratio | 1 | 2013 | 9684 | 0.010 |
Why?
|
Pneumonia | 1 | 2012 | 2164 | 0.010 |
Why?
|
Radionuclide Imaging | 1 | 2005 | 1998 | 0.010 |
Why?
|
Risk Management | 1 | 2004 | 558 | 0.010 |
Why?
|
Survival Analysis | 1 | 2012 | 10115 | 0.010 |
Why?
|
Sex Distribution | 1 | 2004 | 2280 | 0.010 |
Why?
|
Probability | 1 | 2004 | 2483 | 0.010 |
Why?
|
Medical Records Systems, Computerized | 1 | 2005 | 1196 | 0.010 |
Why?
|
Intracranial Hemorrhages | 1 | 2004 | 811 | 0.010 |
Why?
|
Age Distribution | 1 | 2004 | 2875 | 0.010 |
Why?
|
Costa Rica | 1 | 1998 | 186 | 0.010 |
Why?
|
Reed-Sternberg Cells | 1 | 1998 | 78 | 0.010 |
Why?
|
Viral Matrix Proteins | 1 | 1998 | 193 | 0.010 |
Why?
|
Prostate | 1 | 2005 | 1781 | 0.010 |
Why?
|
Mutation | 1 | 2021 | 30266 | 0.010 |
Why?
|
Forecasting | 1 | 2005 | 2945 | 0.010 |
Why?
|
Neoplasm Invasiveness | 1 | 2004 | 3629 | 0.010 |
Why?
|
Quality Assurance, Health Care | 1 | 2005 | 2182 | 0.010 |
Why?
|
Immunophenotyping | 1 | 1998 | 1866 | 0.010 |
Why?
|
Biopsy | 1 | 2005 | 6805 | 0.010 |
Why?
|
Patient Care Team | 1 | 2004 | 2528 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2004 | 10765 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 1998 | 6086 | 0.000 |
Why?
|
Research Design | 1 | 2004 | 6214 | 0.000 |
Why?
|
Tomography, X-Ray Computed | 1 | 2011 | 20776 | 0.000 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2005 | 9442 | 0.000 |
Why?
|
Animals | 1 | 2018 | 169335 | 0.000 |
Why?
|
Immunohistochemistry | 1 | 1998 | 11116 | 0.000 |
Why?
|
Hospitalization | 1 | 2004 | 10847 | 0.000 |
Why?
|
Socioeconomic Factors | 1 | 1998 | 7861 | 0.000 |
Why?
|
Cross-Sectional Studies | 1 | 2004 | 26395 | 0.000 |
Why?
|